Synmosa Biopharma Corporation (TPEX:4114)

Taiwan · Delayed Price · Currency is TWD

30.95

+0.15 (0.49%)

Jun 18, 2026, 1:30 PM CST

-6.99% (1Y)

Market Cap	15.47B -0.1%
Revenue (ttm)	6.37B +11.4%
Net Income	806.68M +13.6%
EPS	1.61 +5.9%
Shares Out	499.77M
PE Ratio	19.22
Forward PE	n/a
Dividend	0.85 (2.76%)
Ex-Dividend Date	Jul 11, 2025

Volume	1,056,322
Open	30.80
Previous Close	30.80
Day's Range	30.80 - 31.25
52-Week Range	29.75 - 39.80
Beta	-0.01
Analysts	Hold
Price Target	37.00 (+19.55%)
Earnings Date	Aug 11, 2026

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale r... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1959

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 4114

Full Company Profile

Financial Performance

In 2025, Synmosa Biopharma's revenue was 6.19 billion, an increase of 11.53% compared to the previous year's 5.55 billion. Earnings were 821.85 million, an increase of 20.03%.

Financial Statements